A PHARMACOKINETIC AND PHARMACOGENOMIC STUDY OF PATIENTS WITH HIGH-GRADE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是比较替莫唑胺(TMZ)在严重(3-4级)血小板减少症患者中的药代动力学(PK)谱与在接受标准一线治疗时未出现严重血小板减少症的患者的药代动力学(PK)谱，并确定在接受标准一线治疗时出现血小板减少的高级别胶质瘤患者是否存在O 6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)基因的单核苷酸多态性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this study are to compare the pharmacokinetic (PK) profiles of temozolomide (TMZ) in patients who develop severe (grade 3-4) thrombocytopenia to the PK profiles in patients who do not develop severe thrombocytopenia while receiving standard first-line therapy and to determine if patients with high-grade gliomas who develop thrombocytopenia while receiving standard first-line therapy have any single nucleotide polymorphisms in the O 6-methylguianine-DNA methyltransferase (MGMT) gene.